Mitsubishi Tanabe Pharma Corporation

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharma company that focuses on the development of innovative treatments for chronic kidney disease-related anemia, is maintaining its 'Buy' rating, with a recommended stock price target of $18 compared to the current $8.90, according to an Aegis Capital Corp. report (http://nnw.fm/F4ezY) released on November 15. The rating and suggested stock price were based on discounted cash flow analysis and the estimated 2016-2022 EBITDA, with a discount rate of eight percent, the report said.